Navigation Links
Cambrex Receives Notice Regarding NYSE Listing
Date:4/14/2009

ncluding, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in our annual report on Form 10-K for the year ended December 31, 2008. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, fu
'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... release is available in German . ... around several quantum dots in a semiconductor layer. Quantum dots ... of atomic processes. If a short laser pulse is fired ... the quantum dot experiences a change in the electromagnetic field ... the emission of light by the dot. As soon as ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
(Date:9/30/2014)... ORLANDO, Fla. , Sept. 30, 2014 ... is pleased to announce that it has entered into ... Biotechnologies, Inc. (Tianhe) which has licensed a series of patented ... stem cells for possible clinical applications.  Tianhe is performing ... and Spain using Tianhe,s ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... SAN FRANCISCO, March 27 Nile Therapeutics, Inc. ... development of novel therapeutics for heart failure patients, announced today ... (IND) application materials that Nile submitted to the U.S. Food ... Company,s Phase IIb clinical trial with CD-NP for the treatment ...
... (Nasdaq: WCRX ) announced today that its ... Drug Application for WC 3016, a low-dose oral contraceptive, ... Warner Chilcott , Warner Chilcott is a ... healthcare and dermatology segments of the U.S. pharmaceuticals market. ...
... Companies Will Offer a Personal Health Record ... Keep ,First Puppy, Healthy and Kissably Sweet ... MMR Information Systems, Inc. (OTC Bulletin ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides consumer-controlled ...
Cached Biology Technology:Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure 2Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 2Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 2MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 4
(Date:9/30/2014)... a Salk professor and Howard Hughes Medical Institute ... been named recipients in the 2014 round of ... through the BRAIN (Brain Research through Advancing Innovative ... grant, announced September 30, provides more than $3 ... three years. , The BRAIN Initiative, launched last ...
(Date:9/30/2014)... water may increase the risk of stillbirth and ... by a Boston University School of Public Health ... Environmental Health , compared 1,091 PCE-exposed pregnancies ... Cape Cod, Ma., where water was contaminated in ... the installation of vinyl-lined asbestos cement pipes. PCE ...
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2
... have found a way to pull pure oxygen from ... and a room-temperature glass of water. ,Because oxygen ... using solar electricity to split water into those elements--a ... One of the chief obstacles to that green-energy scenario ...
... United States, Lyme disease is the most frequently reported ... These animal-borne diseases can make people very sick, and ... crucial to protecting the public. Scientists at the Cary ... $750,000 in grant funding from the U.S. Environmental Protection ...
... University of New Hampshire researchers have tagged one ... They are the first free-swimming leatherbacks ever tagged in ... an endangered species, were tagged July 17, 26 and ... tracking data, allowing scientists to better understand these elusive, ...
Cached Biology News:Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2UNH researchers tag first-ever free-swimming leatherback turtles in New England 2UNH researchers tag first-ever free-swimming leatherback turtles in New England 3
... suspension array system, 100-240 V, uses multiplex ... quantitative analysis of up to 100 proteins ... The suspension array is composed of up ... which may be conjugated with a unique ...
... (HTF) system, 100-240 V, is an optional ... that automates delivery of up to 20 ... array reader. The HTF system automatically draws ... container to constantly maintain a reservoir of ...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
Biology Products: